Patient characteristics according to EBER-ISH results
. | Study population,*no. (%) . | EBER-ISH negative, no. (%) . | EBER-ISH positive, no. (%) . | P . |
|---|---|---|---|---|
| Treatment protocol | .28 | |||
| LNH87 | 52 (47) | 28 (43) | 24 (53) | |
| LNH93 | 58 (53) | 37 (57) | 21 (47) | |
| Age | .17 | |||
| 60 y or younger | 55 (50) | 33 (50) | 22 (49) | |
| Older than 60 y | 55 (50) | 32 (50) | 23 (51) | |
| Sex | .02 | |||
| Male | 75 (68) | 39 (60) | 36 (80) | |
| Female | 35 (32) | 26 (40) | 9 (20) | |
| LDH | .20 | |||
| Equal or less than N | 42 (42) | 27 (47) | 15 (31) | |
| Greater than N | 60 (58) | 31 (53) | 29 (69) | |
| Stage | .69 | |||
| I to II | 16 (16) | 10 (17) | 6 (14) | |
| III to IV | 89 (84) | 51 (83) | 38 (86) | |
| PS | .73 | |||
| 0 to 1 | 75 (73) | 43 (75) | 32 (72) | |
| 2 to 4 | 28 (27) | 15 (25) | 13 (28) | |
| Extranodal sites | .37 | |||
| 0 to 1 | 68 (63) | 36 (63) | 32 (72) | |
| 2 or more | 39 (37) | 26 (37) | 13 (28) | |
| IPI risk category | .22 | |||
| Low | 24 (24) | 13 (23) | 11 (25) | |
| Low-intermediate | 32 (32) | 17 (30) | 15 (34) | |
| High-intermediate | 35 (35) | 18 (32) | 17 (39) | |
| High | 9 (9) | 8 (14) | 1 (2) | |
| Bone marrow | .37 | |||
| Normal | 64 (64) | 36 (63) | 28 (74) | |
| Involved | 36 (36) | 22 (37) | 14 (26) | |
| Central nervous system | .64 | |||
| Normal | 105 (95) | 61 (94) | 44 (98) | |
| Involved | 5 (5) | 4 (6) | 1 (2) |
. | Study population,*no. (%) . | EBER-ISH negative, no. (%) . | EBER-ISH positive, no. (%) . | P . |
|---|---|---|---|---|
| Treatment protocol | .28 | |||
| LNH87 | 52 (47) | 28 (43) | 24 (53) | |
| LNH93 | 58 (53) | 37 (57) | 21 (47) | |
| Age | .17 | |||
| 60 y or younger | 55 (50) | 33 (50) | 22 (49) | |
| Older than 60 y | 55 (50) | 32 (50) | 23 (51) | |
| Sex | .02 | |||
| Male | 75 (68) | 39 (60) | 36 (80) | |
| Female | 35 (32) | 26 (40) | 9 (20) | |
| LDH | .20 | |||
| Equal or less than N | 42 (42) | 27 (47) | 15 (31) | |
| Greater than N | 60 (58) | 31 (53) | 29 (69) | |
| Stage | .69 | |||
| I to II | 16 (16) | 10 (17) | 6 (14) | |
| III to IV | 89 (84) | 51 (83) | 38 (86) | |
| PS | .73 | |||
| 0 to 1 | 75 (73) | 43 (75) | 32 (72) | |
| 2 to 4 | 28 (27) | 15 (25) | 13 (28) | |
| Extranodal sites | .37 | |||
| 0 to 1 | 68 (63) | 36 (63) | 32 (72) | |
| 2 or more | 39 (37) | 26 (37) | 13 (28) | |
| IPI risk category | .22 | |||
| Low | 24 (24) | 13 (23) | 11 (25) | |
| Low-intermediate | 32 (32) | 17 (30) | 15 (34) | |
| High-intermediate | 35 (35) | 18 (32) | 17 (39) | |
| High | 9 (9) | 8 (14) | 1 (2) | |
| Bone marrow | .37 | |||
| Normal | 64 (64) | 36 (63) | 28 (74) | |
| Involved | 36 (36) | 22 (37) | 14 (26) | |
| Central nervous system | .64 | |||
| Normal | 105 (95) | 61 (94) | 44 (98) | |
| Involved | 5 (5) | 4 (6) | 1 (2) |
For the entire study population, n = 110; for EBER-ISH-negative population, n = 65; for the EBER-ISH-positive population, n = 45.
N indicates upper limit of normal; PS, Eastern Cooperative Oncology Group performance status.
Some parameters may sum less than 110 due to incomplete data.